- Poster presentation
- Open Access
Personalizing humanized mice with cells obtained from an HIV post treatment controller
© Hauber et al; licensee BioMed Central Ltd. 2014
- Published: 23 May 2014
HIV research greatly benefits from the use of immunodeficient mouse systems that are susceptible to HIV target cells. Usually, immunodeficient mice are transplanted with primary human cells to develop a “human” immune system. Following engraftment, the animals are subsequently infected with HIV. Here, we applied a different approach and personalized mice by directly transplanting cells from an HIV-infected patient.
Materials and methods
CD4+ T cells were isolated from a HIV-infected post treatment controller (PTC) and transplanted into 6 week old Rag2-/-γc-/- (Rag-hu) mice in order to monitor virus replication over time.
Upon presentation to the clinic in 1998, the patient’s viral load was 52.000 HIV copies/ml with near-normal CD4+ T cell count of 491/ul and slightly reduced CD4+/CD8+ ratio of 0,4. Treatment with AZT, 3TC and effavirenz was initiated and the viral load was undetectable after few weeks and undetectable for the next couple of years. In May 2004 therapy was stopped after more then 5 years in an attempt of STI (structured treatment interruption). Remarkably, the viral load stayed below the level of detection with stable CD4+ counts since then. The patient was further analyzed for host factors but neither the HLA molecules (HLA A 01,02, B44, B52) nor a deletion of the CCR5 receptor could account for the control of the virus after treatment interruption.
At 8 weeks after transplantation the mice were engrafted with 15-30% human CD45+CD3+ and significant viral loads (from 3 - 62 x 10E6) were detected. Analysis of lymphoid cells of the spleen, bone marrow, liver and salivary gland demonstrated a fully established HIV infection.
The direct transplantation of patient-derived cells into hemato-lymphoid system mice provides a novel experimental approach to analyze the presence of replication-competent HIV in patients with undetectable viral loads such as, for example, post treatment controllers (PTC).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.